- Home
- DYAI vs MDCX Comparison
DYAI vs MDCX Comparison
Compare DYAI & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DYAI | MDCX |
|---|---|---|
| Founded | 1979 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8M | 31.1M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | DYAI | MDCX |
|---|---|---|
| Price | $0.81 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $23.50 |
| AVG Volume (30 Days) | 33.0K | ★ 402.0K |
| Earning Date | 03-25-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,342,195.00 | N/A |
| Revenue This Year | $12.52 | N/A |
| Revenue Next Year | $92.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $0.92 |
| 52 Week High | $1.73 | $8.94 |
Technical Indicators
Market Signals| Indicator | DYAI | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 35.24 |
| Support Level | $0.80 | $0.92 |
| Resistance Level | $0.90 | $1.16 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 16.86 | 36.11 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.